NEW YORK -- Elan and Theravance reached a $1 billion agreement in which Elan will buy 21% of royalties that Theravance receives from GlaxoSmithKline for four respiratory drugs.
The deal includes Breo Ellipta, a new treatment for chronic obstructive pulmonary disease that received approval from the Food and Drug Administration last week.
Take-Two Interactive Software is expected by analysts on Monday to post fiscal fourth-quarter earnings of 23 cents a share on revenue of $280.1 million.
Cereal company Post Holdings is expected by Wall Street to report fiscal second-quarter earnings of 27 cents a share on revenue of $255.7 million.
Ann Inc. is forecast to post first-quarter earnings of 43 cents a share on sales of $582 million.
Pacific Sunwear is expected by analysts on Monday to post a first-quarter loss of 19 cents a share.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here: Joseph Woelfel
>To submit a news tip, send an email to: firstname.lastname@example.org.